Pfizer CEO Albert Bourla said in a letter Monday the company is discussing with the Indian government how to expedite approval of its Covid-19 vaccine.
“Pfizer is aware that access to vaccines is critical to ending this pandemic. Unfortunately, our vaccine is not registered in India although our application was submitted months ago,” Bourla wrote in a letter to Pfizer colleagues in India. “We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country.”
Bourla said that the company is “deeply concerned” by the critical Covid-19 situation in India and is committed to being a partner in India’s fight against the coronavirus, “quickly working to mobilize the largest humanitarian relief effort in our company’s history.”
Bourla said Pfizer is rushing shipments of medicines from the company that the government of India has identified as part of their treatment protocol. These medicines, valued at over $70 million, are being donated to India and include steroid medications and anticoagulants.
Pfizer Foundation funding is also supporting humanitarian organizations that provide equipment such as ventilators and oxygen concentrators to India.